Microvideos for Improving HPV Vaccination Among Childhood Cancer Survivors
This exploratory mixed-methods study aims to examine receipt of treatment and decision-making among rural cancer patients in Utah. Guided by Conceptual Model of Healthcare Access, the study will integrate, survey and cancer registry data with patient interviews to better understand how travel burden, socioeconomic conditions, health literacy, and other contextual factors shape treatment location and access to care . While the setting of this research is specific to Utah, a state with vast rural regions and only one National Cancer Institute (NCI)-designated cancer center, the findings may inform policy and practice improvements in other states with similar geographic and healthcare infrastructure. Thus, the study has potential relevance for advancing rural cancer equity nationwide.
Understanding how rural cancer patients make treatment decisions is essential to addressing persistent disparities in cancer care access and outcomes. While geographic barriers and structural inequities are well-documented, less is known about the individual and contextual factors that shape patients' choices about where and how to receive treatment. This mixed-methods study will examine receipt of treatment, decision-making, and patient experience among rural cancer patients in Utah, with attention to travel burden, referral pathways, health literacy, and perceived barriers to care.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Tipo di studio
Iscrizione (Stimato)
Fase
- Non applicabile
Contatti e Sedi
Contatto studio
- Nome: Echo Warner, MPH, PhD, SB
- Numero di telefono: 801-244-7040
- Email: echo.warner@hci.utah.edu
Luoghi di studio
-
-
Utah
-
Salt Lake City, Utah, Stati Uniti, 84112
- Reclutamento
- University of Utah
-
Contatto:
- Echo Warner, MPH, PhD, SB
- Numero di telefono: 801-244-7040
- Email: echo.warner@hci.utah.edu
-
Investigatore principale:
- Echo Warner, MPH, PhD, SB
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
- Adulto
Accetta volontari sani
Descrizione
Inclusion Criteria:
- Eligible participants include cancer survivors who are currently ages 18-26 years and who were diagnosed with childhood cancer (ages 0-26 at diagnosis) in the past ten years.
- Currently use Facebook or willing to create a Facebook account to use for the duration of the study.
- At the time of enrollment, have not completed all recommended doses of the HPV vaccine.
Exclusion Criteria:
- Unable to speak and understand English.
- Participants who take part in the Aim 1 focus groups will be ineligible for the Aim 2 social media group.
- Participants who are fully vaccinated for HPV will be ineligible as the goal of Aim 2 is to evaluate the feasibility of the social media campaign for improving vaccine intention among HPV unvaccinated individuals.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Prevenzione
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Altro: HPV Vaccination Education
Microvideos are designed to be <2 minutes long and to address key information on a topic in an engaging and concise manner.
HPV vaccine education will be provided to unvaccinated emerging adult survivors of childhood cancer through a pilot quasi-experimental social media intervention.
|
To educate survivors of childhood cancers about a key cancer prevention strategy, HPV vaccination.
The core microvideos will focus on the 5 Ws of HPV vaccination: Who should get vaccinated, What HPV vaccination protects against, When to get vaccinated, Where to access the vaccine, Why it matters-designed particularly for cancer survivors.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Feasibility of Microvideo education
Lasso di tempo: up to 4 weeks
|
Feasibility will be defined as ≥80% of participants completing the intervention and study surveys.
|
up to 4 weeks
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Acceptability of Microvideo Education
Lasso di tempo: up to 4 weeks
|
Acceptability will be summarized using means, standard deviations, and proportions of participants indicating strong agreement (scores ≥4 out of 5) with positive statements about the microvideos and platform. Scores range from 0-5, with higher scores indicating more positivity about the microvideos and platform, and lower scores indicating less positivity about the microvideos and platform. |
up to 4 weeks
|
|
Satisfaction Acceptability of Microvideo Education
Lasso di tempo: up to 4 weeks
|
Satisfaction will be summarized using means, standard deviations, and proportions of participants indicating strong agreement (scores ≥4 out of 5) with positive statements about the microvideos and platform. Scores range from 0-5, with higher scores indicating more positivity about the microvideos and platform, and lower scores indicating less positivity about the microvideos and platform. |
up to 4 weeks
|
|
HPV Vaccine Intention
Lasso di tempo: up to 4 weeks
|
To assess HPV vaccine intention among unvaccinated emerging adult survivors of childhood cancer through a pilot quasi-experimental social media intervention. This outcome measure will report the count of participants who intended to receive the HPV Vaccine after the microvideo education. |
up to 4 weeks
|
Collaboratori e investigatori
Sponsor
Investigatori
- Investigatore principale: Echo Warner, MPH, PhD, SB, Huntsman Cancer Institute/ University of Utah
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Altri numeri di identificazione dello studio
- 198894
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Vaccinazione HPV
-
H. Lee Moffitt Cancer Center and Research InstituteNational Cancer Institute (NCI)CompletatoVaccino HPV | HPVStati Uniti, Porto Rico
-
University of PennsylvaniaWorld Bank GroupNon ancora reclutamento
-
Centre Hospitalier Universitaire de la RéunionReclutamento
-
University of UtahNational Cancer Institute (NCI)Reclutamento
-
East Carolina UniversityReclutamento
-
Fundación HuéspedMSD Pharmaceuticals LLCCompletato
-
Emory UniversityAttivo, non reclutante
-
University of FloridaNational Cancer Institute (NCI)Attivo, non reclutante
-
Medipol Universitygaziantep university medicine facultyCompletato
-
University of MinnesotaCompletato
Prove cliniche su Microvideos: HPV Vaccination Education
-
University of Arkansas, FayettevilleNational Cancer Institute (NCI); University of California, Los Angeles; Thomas... e altri collaboratoriAttivo, non reclutanteMalattie prevenibili da vaccino | Papilloma-virus umanoStati Uniti
-
Emel GÜÇLÜ CİHANKahramanmaras Sutcu Imam UniversityReclutamentoInfezione da papillomavirus umano (HPV). | Accettazione/Intenzione Vaccinazione HPVTurchia (Türkiye)